<DOC>
	<DOCNO>NCT00045396</DOCNO>
	<brief_summary>Tipifarnib may stop growth cancer cell block enzymes necessary growth . Phase II trial study effectiveness tipifarnib treat patient acute myeloid leukemia myelodysplastic syndrome first complete remission</brief_summary>
	<brief_title>A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA ( R115777 , NSC # 702818 , IND # 58,359 ) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia ( AML ) And High-Risk Myelodysplasia ( MDS )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine duration disease-free survival ( DFS ) overall survival ( OS ) ZARNESTRA administer intensive induction consolidation chemotherapy adult poor risk acute myelogenous leukemia ( AML ) high-risk myelodysplasia ( MDS ) first complete remission ( CR ) . SECONDARY OBJECTIVES : I . To determine tolerability toxicity ZARNESTRA administer chronic dosing schedule 48 week period adult first CR follow intensive cytotoxic chemotherapy . OUTLINE : This multicenter study . Patients receive oral tipifarnib twice daily day 1-14 . Treatment repeat every 21 day 16 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 14-44 patient accrue study within 11-15 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Pathological Confirmation Diagnosis AML , MDS PMNs &gt; = 1,000/ul Platelets &gt; = 30,000/ul Hematocrit &gt; = 27 % and/or Hemoglobin &gt; = 9 gm/dl unsupported ECOG Performance Status 02 Patients must able give informed consent Female patient childbearing age must negative pregnancy test AST , ALT Alkaline Phosphatase = &lt; 2.5 x normal Bilirubin = &lt; 1.5 x normal Serum Creatinine = &lt; 2.0 mg/dl Creatinine Clearance &gt; = 40 ml/min Left Ventricular Ejection Fraction &gt; = 25 % Patients poorrisk AML highrisk MDS complete induction consolidation chemotherapy ; poor risk AML define one follow characteristic : Antecedent Hematologic Disorder AML Arising MDS Therapyrelated AML Age &gt; = 60 ( absence favorable cytogenetics ) Adverse Cytogenetics ( i.e. , 5/5q , 7/7q , +8 , 20q , 11q23 abnormality , complex karyotype ; abnormality may consider discression study chair ) Hyperleukocytosis diagnosis ( Blasts &gt; = 30,000/mm^3 diagnosis absence favorable cytogenetics ) High Risk MDS define one follow characteristic : RAEB RAEBt , IPSS Score &gt; = 1.5 ( adverse cytogenetics , &gt; 10 % marrow blast , cytopenias least 2 lineage ) : See Appendix E ( Greenberg , et al . Blood 89:20792088,1997 ) 36 CMML &gt; 5 % marrow blast Therapyrelated MDS Any previous treatment ZARNESTRA Ongoing participation Phase II III clinical trial DFS OS primary endpoint ( unless patient withdrawn trial ) Acute promyelocytic ( FAB M3 ) subtype Presence ( 8 ; 21 ) translocation inversion 16 genotype sole abnormality Eligible curative allogeneic stem cell transplantation Known allergy imidazole drug ( e.g. , ketoconazole , miconazole ) Presence Residual AML ( &gt; 5 % marrow blast ) MDS , Determined Morphology , Flow Cytometry , and/or Cytogenetics Active , Uncontrolled Infection Disseminated Intravascular Coagulation Active CNS Leukemia Concomitant Chemotherapy , Radiation Therapy Immunotherapy Women pregnant lactate eligible trial , investigational agent may harmful develop fetus nursing infant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>